Preliminary attitudes on medications for opioid use disorders (MOUDs) in Southeastern Switzerland and New York City.  Castillo F, Scalise D, Hernandez D, Gupta R, Basaraba CN, Corbeil T, Comer SD, Schneeberger AR.  J Addict Dis. 2023 J...

Using machine learning to study the effect of medication adherence in Opioid Use Disorder.  Warren D, Marashi A, Siddiqui A, Eijaz AA, Pradhan P, Lim D, et al. (2022)  PLoS ONE 17(12): e0278988. doi.org/10.1371/journal.pone.0278988 ht...

Key implementation factors in telemedicine-delivered medications for opioid use disorder: a scoping review informed by normalisation process theory Teck, Joseph Tay Wee et al. The Lancet Psychiatry, Volume 10, Issue 1, 50 - 64  Abstract h...

Suboptimal dosing of opioid agonist treatments - a Literature Review  Al-Dewaissan F.B.A.A., Hill D., Evans L., and Luz T.C.B. HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, Vol. 24 • No. N5 • October 2022 https://www.heroinaddictionrelat...

Treatment History and Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among People Who Inject Drugs.  Ohlendorf E, Perez-Correa A, Riback L, Ghiroli M, Lopez-Castro T, Fox AD.  J Addict Med. 2022 Oct 18. doi: 10.1097...

A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence.  Greenwald MK, Ghosh S, Winston JR.  Contemp Clin Trials Commun. 2022 Oct 18;30:101018. ...